Mesoblast Reports US$30.3M Ryoncil Revenues and Hits Phase 3 Back Pain Trial Target
Mesoblast generated US$30.3 million in Ryoncil net revenues and reduced net operating cash spend to US$4.1 million in the quarter, ending with US$122 million of cash on hand. The company achieved patient recruitment targets in its pivotal Phase 3 chronic low back pain trial and secured a CAR technology license.
1. Quarterly Financial Performance
In the quarter ended March 31, Mesoblast posted US$35.3 million in gross Ryoncil sales, generating US$30.3 million in net revenues, and reduced net operating cash spend to US$4.1 million, closing with US$122 million of cash and equivalents.
2. Clinical Development Progress
Mesoblast achieved the patient recruitment target in its pivotal Phase 3 trial of second-generation rexlemestrocel-L for chronic low back pain, advancing the study into its final enrollment phase ahead of data readout.
3. Regulatory Clearances
The FDA cleared Mesoblast’s registrational trial of Ryoncil in Duchenne muscular dystrophy and approved initiation of an adult SR-aGvHD label extension study, with first clinical sites set to activate this quarter.
4. CAR Technology License Acquisition
Mesoblast secured an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform intended to enhance the potency of mesenchymal stromal cell therapies for inflammatory bowel disease and other autoimmune conditions.